Erasmus

AIM ImmunoTech Provides Second Quarter 2021 Business Update

Retrieved on: 
Tuesday, August 17, 2021
Plasma protein binding, Ovarian cancer, EMA, Degenerative disease, European Union, Research, AIM, Safety, Erasmus, Colorectal cancer, Union, Erasmus MC, University, Virus, Therapy, Survival, Doctor of Philosophy, Prostate cancer, Clinical trial, Liver, Article, Vaccine, CEO, Patient, MD, MDPI, Severe acute respiratory syndrome coronavirus 2, Influenza and Other Respiratory Viruses, Disease, Cisplatin, University of Nebraska Medical Center, EAP, Pembrolizumab, FDA, Neoplasm, Aspirin, Company, Quarantine, Private Securities Litigation Reform Act, Intron, Rhinovirus, Special access program, GLOBE, Lists of diseases, HCT, NYSE, CHDR, Celecoxib, COVID-19, AIM ImmunoTech, Animal, Pharmaceutical industry, Medical imaging

OCALA, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.

Key Points: 
  • OCALA, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.
  • Second Quarter 2021 Financial Highlights:
    As of June 30, 2021, AIM had cash, cash equivalents and marketable securities of $57.3 million, compared to $54.4 million as of December 31, 2020.
  • We continued to make positive clinical and operational progress during the second quarter, commented, Thomas K. Equels, CEO of AIM ImmunoTech.
  • We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Immunicom Continues Successful Immunopheresis® Clinical Trial in Advanced, Non-Small Cell Lung Cancer Treatment with Acibadem University

Retrieved on: 
Monday, August 16, 2021
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Multimedia, Clinical trial, University, SSH, Department, Partnership, Research, TNBC, Growth, Health, Erasmus Programme, Student, CASE, Immunotherapy, Kerem, Acıbadem University, Center, HIV disease progression rates, Society, Lung cancer, Cancer, NSCLC, FDA, Toxicity, Paclitaxel, Principal investigator, Network, Oncology, CEO, Acıbadem University School of Medicine, Medicine, Nursing, Technology, Erasmus, Physician, Hospital, Autoimmune disease, Society for Simulation in Healthcare, CE marking, Trial of the century, Large-cell lung carcinoma, Bed, Disease, Immune system, Acıbadem Healthcare Group, Laboratory, Patient, PD-L1, City, Quality of life, Pharmaceutical industry, Vaccine

Immunicom, Inc. , a clinical stage biotech pioneering non-pharmaceutical immunotherapies, progresses with its cancer clinical trial to evaluate the clinical effectiveness of Immunopheresis in partnership with Acibadem University conducted in Acibadem Healthcare Group hospitals.

Key Points: 
  • Immunicom, Inc. , a clinical stage biotech pioneering non-pharmaceutical immunotherapies, progresses with its cancer clinical trial to evaluate the clinical effectiveness of Immunopheresis in partnership with Acibadem University conducted in Acibadem Healthcare Group hospitals.
  • Immunopheresis is intended to treat cancer while avoiding the typical side-effects, toxicity, and negative impacts on quality of life that are frequently associated with other cancer treatments.
  • Lung cancer is one of the most common cancers in the world and the most prevalent cancer in Turkey.
  • With this clinical trial, Immunicom and Acibadem are centered on demonstrating the effectiveness of Immunicoms Immunopheresis therapy for treating patients facing a highly aggressive form of non-small cell lung cancer.

Erasmus+ 2021 2027: Council reaches a provisional agreement with the European Parliament

Retrieved on: 
Saturday, December 12, 2020
Articles, Education, Organizations, Educational policies and initiatives of the European Union, Erasmus+, Erasmus, European Union, Vocational education, Erasmus Programme

The German presidency of the Council and the European Parliament's negotiating team secured a provisional deal on the Erasmus+ programme for the period 2021-2027.

Key Points: 
  • The German presidency of the Council and the European Parliament's negotiating team secured a provisional deal on the Erasmus+ programme for the period 2021-2027.
  • It will cover not only higher education, but all levels and types of education and training, which is reflected by the kept label "Erasmus+".
  • Further to that, DiscoverEU, European Universities and Centres of vocational excellence initiatives are included in the scope of Erasmus+ 2021-2027.
  • On 15 November 2018, the Council adopted its mandate for negotiations with the European Parliament.

Supporting the recovery of the sport sector and addressing the COVID-19 pandemic: Council adopts conclusions

Retrieved on: 
Tuesday, June 23, 2020
Organizations, International organizations, Catholics, Erasmus+, European Union, Corona, Erasmus

The Council conclusions recommend to member states, the Commission and the sport movement how to address the COVID-19 pandemic in the recovery stage.

Key Points: 
  • The Council conclusions recommend to member states, the Commission and the sport movement how to address the COVID-19 pandemic in the recovery stage.
  • The conclusions invite member states to promote the possibilities for support through EU programmes, funds and initiatives, such as the Erasmus+ programme, the European Solidarity Corps, the Corona Response Investment Initiative (CRII), and the Corona Response Investment Initiative Plus (CRII+).
  • The Commission is invited to regularly inform about possibilities for flexible arrangements regarding the implementation of Erasmus+: Sport, and to reflect on more flexibility mechanisms into future funding programmes in the field of sport.
  • The conclusions were adopted by written procedure.

Highlights - How Covid-19 affects Erasmus and EU Solidarity Corps - Committee on Culture and Education

Retrieved on: 
Wednesday, May 6, 2020
Articles, World, Educational policies and initiatives of the European Union, Organizations, Counter-Reformation, Erasmus, Paremiologists, European Union, Pandemic, Erasmus Programme, Draft:Erasmus generation proposals

4. How many people have benefitted from the Erasmus mobility programme since its introduction? © Mediteraneo/AdobeStock

Key Points: 
  1. How many people have benefitted from the Erasmus mobility programme since its introduction? © Mediteraneo/AdobeStock
    The Covid-19 pandemic has also affected the 170,000 young people involved in Erasmus+ or the European Solidarity Corps. Find out how the EU is helping them.

Erasmus Prize 2020 Awarded to Grayson Perry

Retrieved on: 
Thursday, February 27, 2020
Catholics, Catholicism, Praemium Erasmianum Foundation, Erasmus, Grayson Perry

AMSTERDAM, Feb. 27, 2020 /PRNewswire/ -- The Praemium Erasmianum Foundation has awarded the Erasmus Prize 2020 to the British artist Grayson Perry.

Key Points: 
  • AMSTERDAM, Feb. 27, 2020 /PRNewswire/ -- The Praemium Erasmianum Foundation has awarded the Erasmus Prize 2020 to the British artist Grayson Perry.
  • The theme of the Erasmus Prize this year is The power of the image in the digital era'.
  • Perry receives the prize for the insightful way he tackles questions of beauty and craftsmanship while addressing wider social and cultural issues.
  • To mark the presentation of the Erasmus Prize, the Foundation is organizing a varied programme of events related to Grayson Perry and the theme.

Erasmus Prize 2020 Awarded to Grayson Perry

Retrieved on: 
Thursday, February 27, 2020
Catholics, Catholicism, Praemium Erasmianum Foundation, Erasmus, Grayson Perry

AMSTERDAM, Feb. 27, 2020 /PRNewswire/ -- The Praemium Erasmianum Foundation has awarded the Erasmus Prize 2020 to the British artist Grayson Perry.

Key Points: 
  • AMSTERDAM, Feb. 27, 2020 /PRNewswire/ -- The Praemium Erasmianum Foundation has awarded the Erasmus Prize 2020 to the British artist Grayson Perry.
  • The theme of the Erasmus Prize this year is The power of the image in the digital era'.
  • Perry receives the prize for the insightful way he tackles questions of beauty and craftsmanship while addressing wider social and cultural issues.
  • To mark the presentation of the Erasmus Prize, the Foundation is organizing a varied programme of events related to Grayson Perry and the theme.

The Erasmus Programme

Retrieved on: 
Thursday, January 16, 2020
Academia, Erasmus Programme, Education, Catholics, Erasmus+, Erasmus, Socrates programme, Educational policies and initiatives of the European Union

The Erasmus Programme, known officially as Erasmus+, began its current incarnation in 2014.

Key Points: 
  • The Erasmus Programme, known officially as Erasmus+, began its current incarnation in 2014.
  • Erasmus+ continues a range of European Union (EU) funding streams that have existed since 2007, such as the Socrates Programme and the Lifelong Learning Programme.
  • The Erasmus+ programme is run on run seven yearly cycles and the current cycle will end in 2020.
  • The Education Secrertary Gavin Williamson subsequently said in a parliamentary debate that the UK was open to participation in the next Erasmus+ programme.

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development

Retrieved on: 
Wednesday, June 12, 2019
Health, Biotechnology, Oncology, Pharmaceutical, Research, Science, Erasmus University Rotterdam, Catholics, Erasmus MC, Rotterdam, Erasmus, Catholicism

View the full release here: https://www.businesswire.com/news/home/20190612005251/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190612005251/en/
    Under the MoU, HBM expects to establish laboratory space in Rotterdam to facilitate scientific collaborations with Erasmus MC investigators across multiple departments.
  • Such collaborations between industry and academic institutions like Erasmus MC provide an important avenue for scientists and clinicians to advance basic and clinical science.
  • Harbour BioMed has collaborated with Erasmus MC since its inception in 2016, when the company acquired Harbour Antibodies, an Erasmus MC spin-out commercializing two transgenic mouse platforms for producing fully human antibodies.
  • Since that time, HBM and Erasmus MC have worked closely apply these powerful platform technologies for the discovery of novel therapeutics.

Erasmus+: a turning point in the lives of 5 million European students

Retrieved on: 
Monday, May 20, 2019
Catholics, Educational policies and initiatives of the European Union, Counter-Reformation, Erasmus, Paremiologists, Catholicism, Draft:Erasmus generation proposals, Erasmus Programme

The key findings of the studies are:Erasmus+ helps students find their desired careers and get jobs quickerOver 70% of former Erasmus+ students say that they have a better understanding of what they want to do in their future careers when they return from abroad. Their experience abroad also enables them to re-orient their studies to better match their ambitions. The higher education impact study further reveals that 80% were employed within three months of graduation and 72% say their experience abroad helped them get their first job. Nine in ten Erasmus+ alumni say they make use of the skills and experiences acquired abroad in their daily work. Erasmus+ addresses skills mismatches by focusing on soft and interdisciplinary skills development businesses need.Erasmus+ boosts European sense of belongingMore than 90% of Erasmus+ students also improve their ability to work and collaborate with people from different cultures and feel they have a European identity. The biggest impact is on the students who felt less convinced about the EU prior to their exchange and the students that spent time in a more culturally different country. Of all Erasmus+ students those coming from Eastern Europe identify the most with the EU. Erasmus+ supports digital transformation and social inclusionErasmus+ also boosts innovation capacity of universities, their international engagement and ability to answer the needs of the labour market.

Key Points: 
  • The key findings of the studies are:
    • Erasmus+ helps students find their desired careers and get jobs quicker
  • Over 70% of former Erasmus+ students say that they have a better understanding of what they want to do in their future careers when they return from abroad. Their experience abroad also enables them to re-orient their studies to better match their ambitions. The higher education impact study further reveals that 80% were employed within three months of graduation and 72% say their experience abroad helped them get their first job. Nine in ten Erasmus+ alumni say they make use of the skills and experiences acquired abroad in their daily work. Erasmus+ addresses skills mismatches by focusing on soft and interdisciplinary skills development businesses need.
    • Erasmus+ boosts European sense of belonging
  • More than 90% of Erasmus+ students also improve their ability to work and collaborate with people from different cultures and feel they have a European identity. The biggest impact is on the students who felt less convinced about the EU prior to their exchange and the students that spent time in a more culturally different country. Of all Erasmus+ students those coming from Eastern Europe identify the most with the EU. 
    • Erasmus+ supports digital transformation and social inclusion
    • Erasmus+ also boosts innovation capacity of universities, their international engagement and ability to answer the needs of the labour market.
    • Other findings show that former Erasmus+ students are more satisfied with their jobs compared to those who have not gone abroad.
    • For the first study, almost 77 000 responses, including from around 47 000 Erasmus+ students, 12000 graduates and 10000 staff members with Erasmus+ experience were analysed.